EGFR (K716A/C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.K716A;p.C797S;p.L858R
Components
p.K716Ap.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Fostamatinib | 100.0% | 0.0% | 96.74 |
| 2 | Brigatinib | 96.3% | 3.7% | 82.96 |
| 3 | Dacomitinib | 83.3% | 16.8% | 97.99 |
| 4 | Pacritinib | 82.2% | 17.8% | 88.64 |
| 5 | Gilteritinib | 79.0% | 21.0% | 88.97 |
| 6 | Lazertinib | 59.5% | 40.5% | 97.47 |
| 7 | Osimertinib | 58.2% | 41.8% | 97.24 |
| 8 | Neratinib | 43.3% | 56.7% | 93.18 |
| 9 | Lorlatinib | 36.3% | 63.7% | 97.24 |
| 10 | Canertinib | 29.2% | 70.8% | 96.49 |
| 11 | Vandetanib | 27.3% | 72.7% | 95.74 |
| 12 | Ibrutinib | 27.0% | 73.0% | 94.74 |
| 13 | Abemaciclib | 22.5% | 77.5% | 91.48 |
| 14 | Mobocertinib | 19.6% | 80.4% | 97.22 |
| 15 | Entrectinib | 18.6% | 81.4% | 93.69 |
| 16 | Tucatinib | 16.7% | 83.3% | 99.75 |
| 17 | Tepotinib | 16.4% | 83.6% | 99.75 |
| 18 | Erlotinib | 15.6% | 84.4% | 99.75 |
| 19 | Lapatinib | 15.2% | 84.8% | 99.25 |
| 20 | Tivozanib | 13.9% | 86.1% | 92.42 |
| 21 | Pirtobrutinib | 12.7% | 87.3% | 99.49 |
| 22 | Inavolisib | 12.6% | 87.4% | 100.00 |
| 23 | Repotrectinib | 12.2% | 87.8% | 84.21 |
| 24 | Temsirolimus | 11.4% | 88.6% | 100.00 |
| 25 | Sorafenib | 11.0% | 89.0% | 96.72 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Fostamatinib | 100.0% | 97.8% | +2.2% |
| Brigatinib | 96.3% | 98.5% | -2.1% |
| Dacomitinib | 83.3% | 99.8% | -16.5% |
| Pacritinib | 82.2% | — | — |
| Gilteritinib | 79.0% | 91.0% | -12.0% |
| Lazertinib | 59.5% | 100.0% | -40.5% |
| Osimertinib | 58.2% | 99.1% | -40.9% |
| Neratinib | 43.3% | 100.0% | -56.7% |
| Lorlatinib | 36.3% | — | — |
| Canertinib | 29.2% | 98.4% | -69.2% |
| Vandetanib | 27.3% | 99.3% | -72.0% |
| Ibrutinib | 27.0% | 99.3% | -72.3% |
| Abemaciclib | 22.5% | — | — |
| Mobocertinib | 19.6% | 100.0% | -80.4% |
| Entrectinib | 18.6% | — | — |
| Tucatinib | 16.7% | — | — |
| Tepotinib | 16.4% | — | — |
| Erlotinib | 15.6% | 99.4% | -83.8% |
| Lapatinib | 15.2% | 99.2% | -84.0% |
| Tivozanib | 13.9% | — | — |
| Pirtobrutinib | 12.7% | — | — |
| Inavolisib | 12.6% | — | — |
| Repotrectinib | 12.2% | — | — |
| Temsirolimus | 11.4% | — | — |
| Sorafenib | 11.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms